Tectonic Therapeutic (TECX) Projected to Release Quarterly Earnings on Thursday

Key Points

• Tectonic Therapeutic is expected to report Q3 2026 earnings before the market opens on November 5, with analysts forecasting a loss of $1.3163 per share. The earnings call is scheduled for November 6 at 4:00 p.m. ET.
• The company reported a smaller-than-expected loss of $1.18 per share in the prior quarter, beating the consensus estimate of $1.35. Analysts project full-year and next-year losses of $5.27 and $5.70 per share, respectively.
• TECX shares opened at $20.56, well below their 52-week high of $39.53. Despite the volatility, analysts maintain a consensus “Moderate Buy” rating and a $69.17 price target.

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Tectonic Therapeutic to announce earnings of ($1.3163) per share for the quarter. Parties can check the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.35) by $0.17. On average, analysts expect Tectonic Therapeutic to post ($5.27) EPS for the current fiscal year and ($5.70) EPS for the next fiscal year.

Tectonic Therapeutic Stock Performance

NASDAQ:TECX opened at $20.56 on Thursday. The firm's fifty day moving average is $26.66 and its 200-day moving average is $27.99. Tectonic Therapeutic has a 52 week low of $15.52 and a 52 week high of $39.53. The firm has a market cap of $401.93 million, a P/E ratio of -4.50 and a beta of 3.28.

Wall Street Analyst Weigh In

TECX has been the subject of a number of analyst reports. TD Cowen reissued a "buy" rating on shares of Tectonic Therapeutic in a research note on Wednesday, September 30th. Oppenheimer reaffirmed an "outperform" rating and set a $80.00 price target on shares of Tectonic Therapeutic in a research report on Wednesday, September 30th. Wells Fargo & Company decreased their price target on Tectonic Therapeutic from $101.00 to $93.00 and set an "overweight" rating for the company in a report on Friday, August 7th. Zacks Research upgraded Tectonic Therapeutic from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 18th. Finally, Wall Street Zen lowered Tectonic Therapeutic from a "sell" rating to a "strong sell" rating in a research report on Sunday, October 18th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $69.17.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc is a clinical-stage biotechnology company focused on developing medicines that target G protein-coupled receptors (GPCRs), a large class of cell-surface proteins involved in numerous biological processes and diseases. The company seeks to address GPCRs that have historically been difficult to target with conventional drug-discovery methods.

Tectonic Therapeutic uses its proprietary GEODe platform to identify and develop antibodies and other biologic medicines against GPCRs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.